Use of a Synthetic Macromolecule (Hydroxypropyl Cellulose ) and Trehalose as Additives for Oocyte Vitrification
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is aimed to evaluate the use of Hydroxypropyl Cellulose (HPC) as substitute for the traditional protein supplement (Synthetic Serum Substitute; SSS) and Trehalose as substitute for the most widely used sugar (Sucrose) in the vitrification solutions employed for oocyte vitrification.
| Condition | Intervention |
|---|---|
|
Infertility |
Procedure: Synthetic macromolecule HPC and trehalose Procedure: SSS containing HSA and sucrose |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) |
| Official Title: | "Impact of Using Hydroxypropyl Cellulose (HPC) and Trehalose for Oocyte Vitrification in an Ovum Donation Program" |
- Survival after oocyte vitrification using cryoprotective solutions containing hiroxipropilcelulosa (HPC) and trehalose. [ Time Frame: >2 hours ] [ Designated as safety issue: No ]After warming and embryo transfer. Survival will be evaluated morphologically two hours after warming.
- Embryo development [ Time Frame: From time of thawing until pregnancy outcome (0-9 months) ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 402 |
| Study Start Date: | November 2012 |
| Estimated Primary Completion Date: | May 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Vitrified oocytes using HPC+Trehalose
Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
|
Procedure: Synthetic macromolecule HPC and trehalose
Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
|
|
Active Comparator: Vitrified oocytes using SSS+ Sucrose
Oocytes are vitrified using the SSS containing HSA and sucrose
|
Procedure: SSS containing HSA and sucrose
• Oocytes are vitrified using the SSS containing HSA and sucrose
|
Detailed Description:
Vitrification involves the transformation of an aqueous solution into a very viscous solid avoiding ice formation. To achieve this, the vitrification protocols include high concentrations of cryoprotectants dissolved in a base medium supplemented with serum rich in protein. Traditionally available preparations contains human albumin (HSA). The most commonly used in vitrification solutions is the synthetic serum replacement (SSS) consisting of synthetic glycoporoteins and HSA. The replacement of human albumin by other fully synthetic components enables compliance with the European directives for classification of Class III medical device in accordance with the Manual for the Classification of Medical Devices in the regulatory framework of the European community, and therefore these media have the European CE conformity marking (Directive 93/42/EEC). According to European regulations, Class III medical devices are subject to special supervision and require certification exam or design type examination by a notified body. Commercial media supplied by Kitazato supplies ® (Tokyo, Japan) to be used in this study have been submitted to the whole process of evaluation and certification by the notified body BSI0086. Because of physical properties of hydroxypropyl cellulose (HPC), fully synthetic macromolecule, including the ability to form a viscous gel at low temperatures, this macromolecule has been proposed as a substitute for human origin albumin (HSA). Another necessary component of vitrification media is sucrose, which acts as an osmotic agent. Trehalose, a disaccharide present in nature is used by certain species to survive extreme conditions, being able to remain vitrified for years. This sugar has also been employed previously in cryobiology in some vitrification protocols. We have tested HPC and threhalose for oocytes vitrification in a pilot study, showing that no impairment in the survival rates, embryo development and pregnancy rates. The current study is a prospective randomized trial aimed to assess the outcome of ovum donation cycles conducted with vitrified oocytes using HPC and trehalose versus oocytes vitrified using traditional available solutions containing HAS and sucrose.
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Donors:
- < 35 years old
- Normal physical and gynecological examinations
- No family history of hereditary or chromosomal diseases.
- Normal karyotype
- Negative screening for sexually transmitted diseases.
Oocyte recipients:
- Oocyte recipients < 50 years old
- Body mass index< 30
- < 2 previous IVF failures
- No severe male factor
- No recurrent miscarriage
- No hidrosalpinx
- No myoma
- No adenomyosis
- No AMH alterations
Exclusion Criteria:
Donors and recipients not meeting inclusion criteria
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Ana Cobo, Cryobiology Unit Director at IVI Valencia, Instituto Valenciano de Infertilidad, Spain |
| ClinicalTrials.gov Identifier: | NCT01745523 History of Changes |
| Other Study ID Numbers: | 1206-C-103-AC, ClinicalTrials.gov |
| Study First Received: | November 29, 2012 |
| Last Updated: | December 7, 2012 |
| Health Authority: | Spain: Ministry of Health |
Keywords provided by Instituto Valenciano de Infertilidad, Spain:
|
Oocyte vitrification survival rate egg banking ovum donation |
Additional relevant MeSH terms:
|
Infertility Genital Diseases, Male Genital Diseases, Female Benzocaine Anesthetics, Local Anesthetics Central Nervous System Depressants |
Physiological Effects of Drugs Pharmacologic Actions Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on June 18, 2013